236 related articles for article (PubMed ID: 37498380)
21. Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization.
Hsu SJ; Xu X; Chen MP; Zhao ZY; Wang Y; Yin X; Zhang L; Ge NL; Chen Y; Wang YH; Luo JF; Ren ZG; Chen RX
Acad Radiol; 2021 Nov; 28 Suppl 1():S157-S166. PubMed ID: 33653656
[TBL] [Abstract][Full Text] [Related]
22. Deep learning nomogram based on Gd-EOB-DTPA MRI for predicting early recurrence in hepatocellular carcinoma after hepatectomy.
Yan M; Zhang X; Zhang B; Geng Z; Xie C; Yang W; Zhang S; Qi Z; Lin T; Ke Q; Li X; Wang S; Quan X
Eur Radiol; 2023 Jul; 33(7):4949-4961. PubMed ID: 36786905
[TBL] [Abstract][Full Text] [Related]
23. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
Hu J; Bao Q; Cao G; Zhu X; Yang R; Ji X; Xu L; Zheng K; Li W; Xing B; Wang X
Cardiovasc Intervent Radiol; 2020 Jul; 43(7):996-1005. PubMed ID: 31974744
[TBL] [Abstract][Full Text] [Related]
24. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma: Radiologic and Clinical Factors Predictive of Survival.
Kim B; Won JH; Kim J; Kwon Y; Cho HJ; Huh J; Kim JK
AJR Am J Roentgenol; 2021 Jun; 216(6):1566-1573. PubMed ID: 33852336
[No Abstract] [Full Text] [Related]
25. Postprogression treatment of lenvatinib plus PD-1 inhibitor in advanced hepatocellular carcinoma refractory to hepatic arterial infusion chemotherapy.
An C; Fu Y; Li W; Zuo M; Wu P
Cancer; 2023 Jul; 129(14):2235-2244. PubMed ID: 37029486
[TBL] [Abstract][Full Text] [Related]
26. Long-term clinical outcomes of hepatic arterial infusion chemotherapy with cisplatin with or without 5-fluorouracil in locally advanced hepatocellular carcinoma.
Kim BK; Park JY; Choi HJ; Kim DY; Ahn SH; Kim JK; Lee DY; Lee KH; Han KH
J Cancer Res Clin Oncol; 2011 Apr; 137(4):659-67. PubMed ID: 20552225
[TBL] [Abstract][Full Text] [Related]
27. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin in Hepatocellular Cancer with Extrahepatic Spread.
Lyu N; Kong Y; Pan T; Mu L; Li S; Liu Y; Deng H; Li J; Shi M; Xu L; Guo R; Chen M; Wu P; Zhao M
J Vasc Interv Radiol; 2019 Mar; 30(3):349-357.e2. PubMed ID: 30819477
[TBL] [Abstract][Full Text] [Related]
28. Randomized, phase II trial of sequential hepatic arterial infusion chemotherapy and sorafenib versus sorafenib alone as initial therapy for advanced hepatocellular carcinoma: SCOOP-2 trial.
Kondo M; Morimoto M; Kobayashi S; Ohkawa S; Hidaka H; Nakazawa T; Aikata H; Hatanaka T; Takizawa D; Matsunaga K; Okuse C; Suzuki M; Taguri M; Ishibashi T; Numata K; Maeda S; Tanaka K
BMC Cancer; 2019 Oct; 19(1):954. PubMed ID: 31615466
[TBL] [Abstract][Full Text] [Related]
29. Treatment efficacy by hepatic arterial infusion chemotherapy vs. sorafenib after liver-directed concurrent chemoradiotherapy for advanced hepatocellular carcinoma.
Han S; Choi HJ; Beom SH; Kim HR; Lee H; Lee JS; Lee HW; Park JY; Kim SU; Kim DY; Ahn SH; Han KH; Seong J; Won JY; Kim BK
J Cancer Res Clin Oncol; 2021 Oct; 147(10):3123-3133. PubMed ID: 33893539
[TBL] [Abstract][Full Text] [Related]
30. A CT-based deep learning radiomics nomogram for predicting the response to neoadjuvant chemotherapy in patients with locally advanced gastric cancer: A multicenter cohort study.
Cui Y; Zhang J; Li Z; Wei K; Lei Y; Ren J; Wu L; Shi Z; Meng X; Yang X; Gao X
EClinicalMedicine; 2022 Apr; 46():101348. PubMed ID: 35340629
[TBL] [Abstract][Full Text] [Related]
31. Development and validation of a deep learning radiomics nomogram for preoperatively differentiating thymic epithelial tumor histologic subtypes.
Chen X; Feng B; Xu K; Chen Y; Duan X; Jin Z; Li K; Li R; Long W; Liu X
Eur Radiol; 2023 Oct; 33(10):6804-6816. PubMed ID: 37148352
[TBL] [Abstract][Full Text] [Related]
32. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Sorafenib for Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization: Retrospective Subgroup Analysis of 2 Prospective Trials.
Huang Y; Zhang L; He M; Lai Z; Bu X; Wen D; Li Q; Xu L; Wei W; Zhang Y; Zhou Z; Chen M; Guo R; Shi M; Kan A
Technol Cancer Res Treat; 2022; 21():15330338221117389. PubMed ID: 36529949
[No Abstract] [Full Text] [Related]
33. Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study.
Deng M; Lei Q; Wang J; Lee C; Guan R; Li S; Wei W; Chen H; Zhong C; Guo R
Int J Surg; 2023 May; 109(5):1299-1310. PubMed ID: 37038994
[TBL] [Abstract][Full Text] [Related]
34. Magnetic Resonance Deep Learning Radiomic Model Based on Distinct Metastatic Vascular Patterns for Evaluating Recurrence-Free Survival in Hepatocellular Carcinoma.
Zhang C; Ma LD; Zhang XL; Lei C; Yuan SS; Li JP; Geng ZJ; Li XM; Quan XY; Zheng C; Geng YY; Zhang J; Zheng QL; Hou J; Xie SY; Lu LH; Xie CM
J Magn Reson Imaging; 2024 Jul; 60(1):231-242. PubMed ID: 37888871
[TBL] [Abstract][Full Text] [Related]
35. Hepatic artery infusion chemotherapy combined with the FOLFOX regimen for the treatment of hepatocellular carcinoma: recent advances and literature review.
Zhu S; Yu Y; Yang M; Liu X; Lai M; Zhong J; Zhao X; Lu L; Liu Y
Expert Rev Anticancer Ther; 2024 Jun; 24(6):423-434. PubMed ID: 38651280
[TBL] [Abstract][Full Text] [Related]
36. A comparative study between sorafenib and hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Song DS; Song MJ; Bae SH; Chung WJ; Jang JY; Kim YS; Lee SH; Park JY; Yim HJ; Cho SB; Park SY; Yang JM
J Gastroenterol; 2015 Apr; 50(4):445-54. PubMed ID: 25027973
[TBL] [Abstract][Full Text] [Related]
37. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma.
Kim HY; Kim JD; Bae SH; Park JY; Han KH; Woo HY; Choi JY; Yoon SK; Jang BK; Hwang JS; Kim SG; Kim YS; Seo YS; Yim HJ; Um SH;
Korean J Hepatol; 2010 Dec; 16(4):355-61. PubMed ID: 21415578
[TBL] [Abstract][Full Text] [Related]
38. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
[TBL] [Abstract][Full Text] [Related]
39. Prognostic nomogram predicting survival of patients with unresectable hepatocellular carcinoma after hepatic arterial infusion chemotherapy.
Mei J; Lin WP; Shi F; Wei W; Liang JB; Shi M; Zheng L; Li SH; Guo RP
Eur J Radiol; 2021 Sep; 142():109890. PubMed ID: 34375811
[TBL] [Abstract][Full Text] [Related]
40. Randomized, prospective, comparative study on the effects and safety of sorafenib vs. hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis.
Choi JH; Chung WJ; Bae SH; Song DS; Song MJ; Kim YS; Yim HJ; Jung YK; Suh SJ; Park JY; Kim DY; Kim SU; Cho SB
Cancer Chemother Pharmacol; 2018 Sep; 82(3):469-478. PubMed ID: 29982870
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
